Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Miyazaki, S.
Right arrow Articles by Yamaguchi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyazaki, S.
Right arrow Articles by Yamaguchi, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 723-726
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including ß-lactamase-negative ampicillin-resistant strains

Shuichi Miyazakia,*, Toshihiko Fujikawaa, Katsumori Kanazawab and Keizo Yamaguchia

a Department of Microbiology, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo143-8540; b Sumitomo Pharmaceuticals Research Centre, Osaka, Japan

The in vitro activity of ampicillin, cefotaxime, meropenem, panipenem, imipenem and biapenem was assayed using ampicillin-susceptible, ß-lactamase-positive and ß-lactamase-negative ampicillin-resistant (BLNAR) Haemophilus influenzae isolated recently in Japan. Against ampicillin-susceptible isolates, cefotaxime was the most potent (MIC90 0.016 mg/mL). Both cefotaxime and meropenem (MIC90 of both, 0.5 mg/L) were the most potent against ß-lactamase-positive isolates. Against BLNAR isolates, meropenem (MIC90 0.5 mg/L) was the most potent. In murine bronchopneumonia caused by ampicillin-susceptible and BLNAR H. influenzae, cefotaxime showed the best efficacy, followed by meropenem. Our results indicate that meropenem could be a useful intravenous agent for infections caused by H. influenzae, including BLNAR strains.

* Corresponding author. Tel: +81-3-3762-4151; Fax: +81-3-5493-5415; E-mail: shuichi{at}med.toho-u.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. Hotomi, K. Fujihara, D. S. Billal, K. Suzuki, T. Nishimura, S. Baba, and N. Yamanaka
Genetic Characteristics and Clonal Dissemination of {beta}-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzae Strains Isolated from the Upper Respiratory Tract of Patients in Japan
Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3969 - 3976.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Cerquetti, M. Giufre, R. Cardines, and P. Mastrantonio
First Characterization of Heterogeneous Resistance to Imipenem in Invasive Nontypeable Haemophilus influenzae Isolates
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3155 - 3161.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
W.-C. Ko, H.-C. Lee, S.-R. Chiang, J.-J. Yan, J.-J. Wu, C.-L. Lu, and Y.-C. Chuang
In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain
J. Antimicrob. Chemother., February 1, 2004; 53(2): 393 - 395.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.